Aravive, Inc. Gains 30.53%
Tue, Nov 01, 2022 at 07:27 PM
Aravive, Inc. (ARAV:NASDAQ) shot up at $1.71, representing a gain of 30.5%. On Tue, Nov 01, 2022, ARAV:NASDAQ hit a New 2-Week High of $1.71. The stock got featured on our News Catalysts scanner on Tue, Oct 25, 2022 at 09:12 AM in the 'PRIVATE PLACEMENT' category. From Tue, Oct 18, 2022, the stock recorded 60.00% Up Days and 54.55% Green Days
About Aravive, Inc. (ARAV:NASDAQ)
Versartis Inc is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency.
Top 10 Gainers:
- Abiomed, Inc. (ABMD:NASDAQ), 49.88%
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 46.63%
- Bull Horn Holdings Corp. (BHSE:NASDAQ), 44.67%
- NLS Pharmaceutics Ltd. (NLSP:NASDAQ), 44%
- Ucommune International Ltd (UK:NASDAQ), 34.65%
- Safe-T Group Ltd (SFET:NASDAQ), 30.7%
- Aravive, Inc. (ARAV:NASDAQ), 30.53%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 25.13%
- IDEX Biometrics ASA (IDBA:NASDAQ), 23.01%
- Harsco Corporation (HSC:NYSE), 22.5%